Altaf Mohammed
YOU?
Author Swipe
View article: Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer
Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer Open
Prophylactic treatment with selective estrogen receptor modulators (SERMs) and aroma-tase inhibitors (AIs) targeting the nuclear estrogen receptor (ER) can prevent the formation of ER-positive tumors in women at high risk for breast cancer…
View article: Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via <scp>MHC</scp> upregulation and remodeling of the immune cell niche
Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via <span>MHC</span> upregulation and remodeling of the immune cell niche Open
A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon‐γ signaling as a key pathway. In this study, we combine intermitt…
View article: [Corrigendum] Chemopreventive effects of PBI‑Se, a selenium‑containing analog of PBIT, on AOM‑induced aberrant crypt foci in F344 rats
[Corrigendum] Chemopreventive effects of PBI‑Se, a selenium‑containing analog of PBIT, on AOM‑induced aberrant crypt foci in F344 rats Open
Following the publication of the above article, an interested reader drew to the authors' attention that the RT‑PCR data panels shown in Fig. 3C, showing the effects of PBIT and PBI‑Se treatment on endogenous IL‑8 mRNA expression levels in…
View article: Natural Products for Cancer Prevention and Interception: Preclinical and Clinical Studies and Funding Opportunities
Natural Products for Cancer Prevention and Interception: Preclinical and Clinical Studies and Funding Opportunities Open
Multiple agents derived from natural products (NPs) have been evaluated for cancer prevention and interception, either alone or in combination. The National Cancer Institute (NCI) is very interested in advancing research to identify additi…
View article: Green Cancer Prevention and Beyond
Green Cancer Prevention and Beyond Open
The concept of green chemoprevention was introduced in 2012 by Drs. Jed Fahey and Thomas Kensler as whole-plant foods and/or extract-based interventions demonstrating cancer prevention activity. Refining concepts and research demonstrating…
View article: Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats
Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats Open
Non-steroidal anti-inflammatory drugs (NSAIDs) are promising colorectal cancer (CRC) chemopreventive drugs; however, to overcome NSAIDs’ associated side effects, there is a need to develop safer and efficacious approaches. The present stud…
View article: Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S1
View article: Data from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Data from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establish…
View article: Supplementary Table S2 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S2 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S2
View article: Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S4
View article: Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S3
View article: Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S3
View article: Supplementary Figures from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Figures from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Supplementary Figures S1-9
View article: Supplementary Figures from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Figures from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Supplementary Figures S1-9
View article: Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S4
View article: Supplementary Table S2 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S2 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S2
View article: Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer Open
Table S1
View article: Supplementary Figure 1B from Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis
Supplementary Figure 1B from Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis Open
Supplementary Figure 1B. Effect of Frondanol A5 treatment on colon tumor (CT) cell proliferation
View article: Supplementary Tables from Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers
Supplementary Tables from Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers Open
Supplementary Tables
View article: Supplementary Data legends from Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model
Supplementary Data legends from Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model Open
Supplementary Data legends
View article: Supplementary Figure 1 from Chemoprevention of Colon and Small Intestinal Tumorigenesis in APC<sup>Min/+</sup> Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention
Supplementary Figure 1 from Chemoprevention of Colon and Small Intestinal Tumorigenesis in APC<sup>Min/+</sup> Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention Open
PDF file - 4441KB
View article: Supplementary Table from Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model
Supplementary Table from Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model Open
Supplementary Table 1
View article: Data from The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-Kras<sup>G12D/+</sup> Transgenic Mouse Model
Data from The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-Kras<sup>G12D/+</sup> Transgenic Mouse Model Open
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy with a dismal prognosis. Developing novel strategies to prevent or delay pancreatic cancer is currently of intense interest. The chemopreventive efficacy of g…
View article: Supplementary Figure 1B from Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis
Supplementary Figure 1B from Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis Open
Supplementary Figure 1B. Effect of Frondanol A5 treatment on colon tumor (CT) cell proliferation
View article: Supplementary Table 1 from Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling
Supplementary Table 1 from Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling Open
Supplementary Table 1. List of primers used for real-time PCR analysis
View article: Supplementary Figure 2 from Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling
Supplementary Figure 2 from Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling Open
Supplementary Figure 2. Western Immunoblotting for c-Myc, p21 and ODC in MiaPaCa cells
View article: Supplementary Figure from Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
Supplementary Figure from Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer Open
Supplementary Figure from Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
View article: Data from Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP)
Data from Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP) Open
A clinical trial in patients with familial adenomatous polyposis (FAP) demonstrated that sulindac plus erlotinib (SUL+ERL) had good efficacy in the duodenum and colon, but toxicity issues raised concerns for long-term prevention. We perfor…